Itraconazole Prevents Invasive Fungal Infections in Neutropenic Patients Treated for Hematologic Malignancies: Evidence From a Meta-Analysis of 3,597 Patients
- 15 December 2003
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (24) , 4615-4626
- https://doi.org/10.1200/jco.2003.04.052
Abstract
Purpose: Efficacy of antifungal prophylaxis has not yet been convincingly proven in numerous trials of various antifungals. New evidence and the anti-Aspergillus efficacy of itraconazole prompted a new look at the data for the prevention of invasive fungal infections. Patients and Methods: Randomized, controlled studies with itraconazole for antifungal prophylaxis in neutropenic patients with hematologic malignancies were identified from electronic databases and hand searching. Results: Thirteen randomized trials included 3,597 patients who were assessable for invasive fungal infections. Itraconazole reduced the incidence of invasive fungal infection (mean relative risk reduction, 40% ± 13%; P = .002), the incidence of invasive yeast infections (mean, 53% ± 19%; P = .004) and the mortality from invasive fungal infections (mean, 35% ± 17%; P = .04) significantly. The incidence of invasive Aspergillus infections was only reduced in trials using the itraconazole cyclodextrine solution (mean, 48% ± 21%; P = .02) and not itraconazole capsules (mean, 75% ± 73% increase; P = .3). The overall mortality was not changed. Adverse effects were rare, hypokalemia was noted in three studies, and a higher rate of drug discontinuation was found in trials that compared itraconazole cyclodextrine solution to a control without cyclodextrine. The effect of prophylaxis was clearly associated with a higher bioavailable dose of itraconazole. Conclusion: Antifungal prophylaxis with itraconazole effectively prevents proven invasive fungal infections and—shown for the first time for antifungal prophylaxis—reduces mortality from these infections and the rate of invasive Aspergillus infections in neutropenic patients with hematologic malignancies. Adequate doses of the oral cyclodextrine solution (at least 400 mg/d) or IV formulations (200 mg/d) of itraconazole are necessary for these effects.Keywords
This publication has 37 references indexed in Scilit:
- Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solutionAnnals of Hematology, 2003
- Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized TrialAnnals of Internal Medicine, 2003
- Antifungal prophylaxis for severely neutropenic chemotherapy recipientsCancer, 2002
- Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International ConsensusClinical Infectious Diseases, 2002
- Aspergillosis Case-Fatality Rate: Systematic Review of the LiteratureClinical Infectious Diseases, 2001
- Prophylactic action of oral fluconazole against fungal infection in neutropenic patientsCancer, 2000
- Towards a targeted, risk‐based, antifungal strategy in neutropenic patientsBritish Journal of Haematology, 2000
- Candidemia in Allogeneic Blood and Marrow Transplant Recipients: Evolution of Risk Factors after the Adoption of Prophylactic FluconazoleThe Journal of Infectious Diseases, 2000
- Candidemia in Cancer Patients: A Prospective, Multicenter Surveillance Study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)Clinical Infectious Diseases, 1999
- Efficacy of Itraconazole in the Prevention of Fungal Infections Among Neutropenic Patients with Hematologic Malignancies and Intensive Chemotherapy. A Double Blind, Placebo Controlled StudyLeukemia & Lymphoma, 1993